A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

Portfolio manager Eden Rahim sees biotech entering a new bull market amid lower rates, better trial data and renewed investor ...

NFL star Tom Brady has cloned his late pit bull mix, Lua, creating a new dog named Junie. Invested in biotech firm Colossal ...

New Wave Biotech has launched a new Life Cycle Assessment (LCA) tool tailored to the biotechnology sector, designed to provide real-time visibility into the ...

A Durham biotech with big-name backers is closing its doors, leaving questions about the future of its crop protection ...

Azalea's first drug candidate is a CAR-T therapy for cancer and autoimmune conditions that turns immune cells into cancer ...

Colossal Biosciences, which has brought to life a small pack of genetically modified dire wolves, has acquired cloning ...

Although heart cells and skin cells contain identical instructions for creating proteins encoded in their DNA, they're able ...

Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...

Less than two years after emerging, Arena BioWorks is shuttering, citing the “adverse impact of biotech macro conditions” as ...

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

Amid historic advances in cell-based therapies and precision medicine, biotech’s biggest challenge isn’t scientific, it’s ...